Drug Patents owned by Cmp Dev Llc

1. List of Atorvaliq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11369567 CMP DEV LLC Aqueous suspension suitable for oral administration
Jun, 2037

(14 years from now)

Drugs and Companies using ATORVASTATIN CALCIUM ingredient

Market Authorisation Date: 01 February, 2023

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage

2. List of Carospir drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11395828 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(13 years from now)

US11491166 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(13 years from now)

US10888570 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(13 years from now)

US10660907 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(13 years from now)

US10624906 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(13 years from now)

US9757394 CMP DEV LLC Spironolactone aqueous formulations
Oct, 2036

(13 years from now)

US10493083 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(13 years from now)

US11389461 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(13 years from now)

Drugs and Companies using SPIRONOLACTONE ingredient

Market Authorisation Date: 04 August, 2017

Treatment: Carospir is indicated for treatment of nyha class iii-iv heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure; C...

Dosage: SUSPENSION;ORAL

How can I launch a generic of CAROSPIR before it's patent expiration?
More Information on Dosage

CAROSPIR family patents

12

United States

1

Morocco

1

Canada

1

European Union

3. List of Norliqva drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458095 CMP DEV LLC NA
Feb, 2041

(17 years from now)

US11253474 CMP DEV LLC Pharmaceutical solution of amlodipine
Feb, 2041

(17 years from now)

Drugs and Companies using AMLODIPINE BESYLATE ingredient

Market Authorisation Date: 24 February, 2022

Treatment: Norliqva is indicated for the treatment of hypertension, to lower blood pressure in adults and children 6 years of age and older; Norliqva is indicated for the symptomatic treatment of chronic stable ...

Dosage: SOLUTION;ORAL

More Information on Dosage

NORLIQVA family patents

4

United States

4. List of Potassium Phosphates drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10632150 CMP DEV LLC Potassium phosphates composition for injection
Apr, 2039

(16 years from now)

Drugs and Companies using POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC ingredient

Market Authorisation Date: 19 September, 2019

Treatment: Potassium phosphates injection is indicated as a source of phosphorus in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of age and older

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

5. List of Tadliq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11382917 CMP DEV LLC Liquid oral formulations for tadalafil
Dec, 2038

(15 years from now)

Drugs and Companies using TADALAFIL ingredient

Market Authorisation Date: 17 June, 2022

Treatment: Tadliq is indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability

Dosage: SUSPENSION;ORAL

More Information on Dosage

TADLIQ family patents

6

United States

2

India

1

Singapore

1

Brazil

1

Morocco

1

Japan

IB

1

IB

1

Canada

1

Australia

1

China

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic